

In the Specification:

At page 41, line 1, please insert the Abstract herewith submitted.

In the Claims:

Please amend the claims as follows:

15. (Amended) A method of identifying a compound that modulates Annexin-based multidrug resistance (MDR) in a cell, comprising:

a) incubating said cell in the presence of a candidate compound in the presence or absence of a cytotoxic drug; and

b) assessing the effect of said candidate compound on the resistance of said cell to said cytotoxic drug;

wherein a candidate compound is selected as a modulator of Annexin-based MDR, when the resistance of said cell to said cytotoxic drug is measurably different in the presence of said compound as compared to the resistance in the absence of said compound.

16. The method of claim 15, wherein said cell is a cell having been rendered multidrug resistant (MDR) by an expression of an Annexin nucleic acid molecule.

17. The method of claim 15, wherein said compound is selected from the group consisting of a nucleic acid molecule encoding an Annexin variant, or a part thereof,

a dominant negative mutant of an Annexin, a mutant Annexin, an antibody to Annexin, a peptide, and a small molecule.

18. (Amended) The method of claim 17, wherein said candidate compound is an Annexin I antisense nucleic acid.

19. (Amended) The method of claim 15, wherein said cytotoxic drug is an anticancer drug.

20. A method of modulating Annexin-based MDR in a cell comprising: administering thereto an effective amount of a compound selected from the group consisting of a nucleic acid molecule, a dominant negative mutant of an Annexin, a mutant Annexin protein, an antibody to Annexin, a peptide, and a small molecule, whereby said effective amount of said compound modulates Annexin-based MDR in said cell.

21. The method of claim 20, wherein said Annexin-based MDR is Annexin I-based.

22. (Amended) The method of claim 35, wherein said compound is an Annexin I antisense nucleic acid.

23. (Amended) The method of claim 35, wherein said compound is a calcium chelator or a calcium channel blocker.

32. A method of conferring drug resistance to a cell, comprising an increase in the expression of an Annexin protein, whereby said increased expression is capable of conferring MDR in said cell.

33. The method of claim 32, wherein said Annexin protein is Annexin I.

Please add the following new claims:

34. (New Claim) The method of claim 1, wherein said modulator of Annexin-based MDR reduces Annexin-based MDR in a cell.

35. (New Claim) The method of claim 21, wherein said compound reduces Annexin-based MDR in said cell.

36. (New Claim) The method of claim 21, wherein said compound increases Annexin-based MDR in said cell.

REMARKS

Claims 15-23, 32-33 and 34-36 are now in the case. Reconsideration of this Application and entry of the foregoing amendments are respectfully requested.